Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus anlotinib for persistent, recurrent, or metastatic cervical cancer
ChiCTR1900023015Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Started Sep 2019; status: recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900023015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023015.